Last 44 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -2.27 | — | — | 14.90 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 6.33 | 4.19 | 4.95 | 1.03 | 4.63 | 5.51 | 6.64 | 15.42 | 8.89 | 6.25 | 10.89 | 10.73 | 7.83 |
| — | -23.8% | -25.5% | -93.3% | -47.9% | -12.0% | -39.0% | +43.7% | +13.5% | -42.0% | +33.6% | -33.1% | +766.3% | |
| P/B Ratio | 1.99 | 3.09 | 1.98 | 1.34 | 1.51 | 1.77 | 1.70 | 2.47 | 2.53 | 1.99 | 2.14 | 1.77 | 1.90 |
| — | +74.7% | +16.4% | -45.6% | -40.2% | -11.3% | -20.7% | +39.6% | +33.2% | -1.7% | +27.0% | -14.5% | +0.9% | |
| P/FCF | — | — | — | 2.82 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | 4.94 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | 5.42 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
REGENXBIO Inc.'s operating margin was -176.3% in Q3 2025, up 120.0 pp QoQ and up 80.3 pp YoY. The trailing four-quarter average of -175.3% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 321.1% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 59.7% | -107.9% | 57.3% | 96.1% | 70.2% | 48.8% | 34.4% | 45.8% | 29.9% | 57.2% | 52.6% | 78.5% | 59.2% |
| — | -321.1% | +66.8% | +109.8% | +134.9% | -14.6% | -34.6% | -41.6% | -49.5% | +12.9% | -12.9% | +168.3% | -37.1% | |
| Operating Margin | -280.0% | -176.3% | -296.3% | 13.6% | -242.1% | -256.6% | -251.3% | -395.4% | -287.7% | -224.7% | -366.0% | -345.7% | -184.3% |
| — | +31.3% | -17.9% | +103.4% | +15.8% | -14.2% | +31.3% | -14.4% | -56.1% | +16.2% | -91.1% | -7.4% | -334.3% | |
| Net Margin | -272.5% | -208.3% | -331.8% | 6.8% | -241.3% | -246.3% | -237.7% | -405.4% | -283.1% | -214.0% | -360.7% | -348.4% | -191.2% |
| — | +15.4% | -39.6% | +101.7% | +14.8% | -15.1% | +34.1% | -16.4% | -48.1% | +24.8% | -72.7% | -0.9% | -359.3% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -79.5% | -33.0% | -29.1% | 2.3% | -18.2% | -18.3% | -14.3% | -18.0% | -18.6% | -16.1% | -16.5% | -13.6% | -11.1% |
| — | -80.0% | -102.6% | +112.6% | +2.1% | -14.0% | +13.3% | -32.7% | -67.9% | -27.3% | -60.2% | -28.8% | -123.1% | |
| ROA | -43.7% | -11.2% | -13.2% | 1.3% | -10.4% | -11.0% | -8.8% | -10.5% | -10.4% | -9.4% | -10.1% | -8.4% | -7.0% |
| — | -2.3% | -49.5% | +112.1% | +0.2% | -16.5% | +12.3% | -24.8% | -49.2% | -14.4% | -46.2% | -17.6% | -122.7% | |
| ROIC | -53.8% | -13.5% | -21.8% | 3.6% | -12.6% | -12.0% | -9.4% | -11.4% | -12.5% | -11.7% | -12.0% | -9.9% | -8.3% |
| — | -12.8% | -132.6% | +131.5% | -0.6% | -1.9% | +21.7% | -14.9% | -51.0% | -24.7% | -50.8% | -0.7% | -114.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 12.6% YoY to 2.66x, tightening the short-term liquidity position. Debt/Equity has risen for 3 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.32 | 1.66 | 0.36 | 0.29 | 0.32 | 0.28 | 0.46 | 0.44 | 0.29 | 0.25 | 0.23 | 0.20 | 0.18 |
| — | +495.5% | -20.2% | -33.3% | +10.3% | +11.7% | +102.0% | +117.7% | +56.0% | +59.5% | +60.8% | +57.7% | +61.9% | |
| Debt / EBITDA | — | — | — | 4.97 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.69 | 2.66 | 3.13 | 2.93 | 2.69 | 3.05 | 3.53 | 3.59 | 2.57 | 2.87 | 3.21 | 3.46 | 3.19 |
| — | -12.6% | -11.4% | -18.2% | +4.8% | +6.2% | +9.8% | +3.6% | -19.4% | -18.7% | -20.9% | -7.0% | -19.8% | |
| Quick Ratio | 2.69 | 2.66 | 3.13 | 2.93 | 2.69 | 3.05 | 3.53 | 3.59 | 2.57 | 2.87 | 3.21 | 3.46 | 3.19 |
| — | -12.6% | -11.4% | -18.2% | +4.8% | +6.2% | +9.8% | +3.6% | -19.4% | -18.7% | -20.9% | -7.0% | -16.8% | |
| Interest Coverage | -18.43 | -3.98 | -5.76 | 1.42 | -5.45 | -75.70 | -124.80 | -31.30 | -46.88 | -40.00 | -65.28 | -24.01 | -13.40 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 44 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying RGNX stock.
REGENXBIO Inc.'s current P/E is -2.3x. The average P/E over the last 1 quarters is 14.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
REGENXBIO Inc.'s current operating margin is -280.0%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking REGENXBIO Inc.'s business trajectory between earnings reports.